Literature DB >> 25766980

Clinical diagnosis of early dengue infection by novel one-step multiplex real-time RT-PCR targeting NS1 gene.

Je-Hyoung Kim1, Chom-Kyu Chong2, Mangalam Sinniah3, Jeyaindran Sinnadurai3, Hyun-Ok Song4, Hyun Park5.   

Abstract

BACKGROUND: Dengue is a mosquito-borne disease that causes a public health problem in tropical and subtropical countries. Current immunological diagnostics based on IgM and/or nonstructural protein 1 (NS1) antigen are limited for acute dengue infection due to low sensitivity and accuracy.
OBJECTIVES: This study aimed to develop a one-step multiplex real-time RT-PCR assay showing higher sensitivity and accuracy than previous approaches. STUDY
DESIGN: Serotype-specific primers and probes were designed through the multiple alignment of NS1 gene. The linearity and limit of detection (LOD) of the assay were determined. The assay was clinically validated with an evaluation panel that was immunologically tested by WHO and Malaysian specimens.
RESULTS: The LOD of the assay was 3.0 log10 RNA copies for DENV-1, 2.0 for DENV-3, and 1.0 for DENV-2 and DENV-4. The assay showed 95.2% sensitivity (20/21) in an evaluation panel, whereas NS1 antigen- and anti-dengue IgM-based immunological assays exhibited 0% and 23.8-47.6% sensitivities, respectively. The assay showed 100% sensitivity both in NS1 antigen- and anti-dengue IgM-positive Malaysian specimens (26/26). The assay provided the information of viral loads and serotype with discrimination of heterotypic mixed infection.
CONCLUSIONS: The assay could be clinically applied to early dengue diagnosis, especially during the first 5 days of illness and approximately 14 days after infection showing an anti-dengue IgM-positive response.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dengue; Early diagnosis; Heterotypic mixed infection; Multiplex RT-PCR; NS1; Quantitation; Serotyping

Mesh:

Substances:

Year:  2015        PMID: 25766980     DOI: 10.1016/j.jcv.2015.01.018

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Detection of dengue, west Nile virus, rickettsiosis and leptospirosis by a new real-time PCR strategy.

Authors:  Daniel García-Ruíz; Marco A Martínez-Guzmán; Albertina Cárdenas-Vargas; Erika Marino-Marmolejo; Abel Gutiérrez-Ortega; Esteban González-Díaz; Rayo Morfin-Otero; Eduardo Rodríguez-Noriega; Hector Pérez-Gómez; Darwin Elizondo-Quiroga
Journal:  Springerplus       Date:  2016-05-20

2.  Enhanced performance of an innovative dengue IgG/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody and dengue virus antigen.

Authors:  Jihoo Lee; Young-Eun Kim; Hak-Yong Kim; Mangalam Sinniah; Chom-Kyu Chong; Hyun-Ok Song
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

3.  Validation and Application of a Commercial Quantitative Real-Time Reverse Transcriptase-PCR Assay in Investigation of a Large Dengue Virus Outbreak in Southern Taiwan.

Authors:  Huey-Pin Tsai; You-Yuan Tsai; I-Ting Lin; Pin-Hwa Kuo; Kung-Chao Chang; Jung-Chin Chen; Wen-Chien Ko; Jen-Ren Wang
Journal:  PLoS Negl Trop Dis       Date:  2016-10-12

4.  Superficial vimentin mediates DENV-2 infection of vascular endothelial cells.

Authors:  Jie Yang; Lingyun Zou; Yi Yang; Jizhen Yuan; Zhen Hu; Hui Liu; Huagang Peng; Weilong Shang; Xiaopeng Zhang; Junmin Zhu; Xiancai Rao
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

5.  Application of whole genome data for in silico evaluation of primers and probes routinely employed for the detection of viral species by RT-qPCR using dengue virus as a case study.

Authors:  Kevin Vanneste; Linda Garlant; Sylvia Broeders; Steven Van Gucht; Nancy H Roosens
Journal:  BMC Bioinformatics       Date:  2018-09-04       Impact factor: 3.169

6.  Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.

Authors:  Junhyung Cho; Young Jae Lee; Je Hyoung Kim; Sang Il Kim; Sung Soon Kim; Byeong-Sun Choi; Jang-Hoon Choi
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.